MarketBeat
21 Nov 2026, 02:13 UTC · 1h ago
Incyte Maps Post-JAKAFI Growth as Key Drug Data and 2027 Launch Loom
Impact · against what's priced in
The article provides a detailed roadmap for post-Jakafi growth, but most of the strategic targets and pipeline timelines are already accounted for in current valuations. The only marginal novelty is the specific clinical design for the CALR antibody (989), which offers a concrete path to the pipeline optionality the market currently discounts.
- INCY+0.00
Already priced in
- The price assumes
Jakafi's current $3.55bn revenue stream and its modest near-term growth, including the $750m conversion to the new once-daily XR formulation.
The reported 3% conversion rate to Jakafi XR aligns with the company's projections and the market's assumption of modest near-term growth.
What INCY's price assumes · Sep 22

- INCY
- biopharma
- clinical trials
- drug development
- fda
- hematology
- loss of exclusivity
- oncology
- pipeline
- rd spending
Search tags




